合并糖尿病与表型家族性高胆固醇血症患者的心血管结局:一项全国性登记队列研究
瑞典全国登记队列研究纳入2002至2020年糖尿病患者,比较合并或不合并表型家族性高胆固醇血症(FH,荷兰脂质临床网络标准≥6分)者与无糖尿病一般人群对照的心血管事件风险。中位随访14.1年(1型糖尿病)和7.9年(2型糖尿病)。合并糖尿病与表型FH者心血管死亡和心血管事件风险显著高于对照,且LDL-C水平更高。
要点
- 1型糖尿病合并表型FH者心血管死亡风险为对照的21.3倍(HR 21.3,95%CI 14.6-31.0)。
- 2型糖尿病合并表型FH者心血管死亡风险为对照的2.40倍(HR 2.40,95%CI 2.19-2.63)。
- 合并糖尿病与表型FH者LDL-C更高且主要心血管结局风险均增加(P<0.0001)。
核心结论
- 合并糖尿病与表型FH的患者心血管不良结局风险更高,且尽管接受强化降脂治疗,LDL-C水平仍更高。
研究设计与样本
- 瑞典全国性登记队列研究,纳入2002至2020年糖尿病患者。
- 1型糖尿病45,585例(对照227,923例),2型糖尿病655,250例(对照655,250例)。
- 中位随访分别为14.1年和7.9年。
- 采用校正Cox比例风险模型,以无糖尿病一般人群为参照,比较合并或不合并表型FH(荷兰脂质临床网络标准≥6分)者的心血管事件风险。
主要发现
- 1型糖尿病中153例、2型糖尿病中7,197例有表型FH。
- 与对照相比,合并糖尿病与表型FH者心血管死亡风险:1型HR 21.3(95%CI 14.6-31.0),2型HR 2.40(95%CI 2.19-2.63)。
- 与对照相比,合并糖尿病与表型FH者心血管事件风险:1型HR 15.1(95%CI 11.1-20.5),2型HR 2.73(95%CI 2.58-2.89)。
- 与不合并FH的糖尿病患者相比,合并糖尿病与表型FH者观察期间LDL-C水平更高(P<0.05),所有主要心血管结局风险增加(P<0.0001)。
- 表型FH患者接受降脂治疗的比例更高(P<0.0001)。
关键数值与推荐
- 表型FH定义:荷兰脂质临床网络标准评分≥6分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with diabetes or familial hypercholesterolemia (FH) have an increased incidence of cardiovascular diseases compared with the population, but whether this risk is exacerbated in patients with combined traits is unknown. RESEARCH DESIGN AND METHODS: In this Swedish nationwide, register-based cohort study, patients with diabetes were included between 2002 and 2020. Adjusted Cox proportional hazards models were used to assess the risk of cardiovascular events in patients with or without phenotypic FH (≥6 points for phenotypic FH according to Dutch Lipid Clinic Network criteria) compared with general population control subjects without diabetes as reference. RESULTS: A total of 45,585 patients with type 1 diabetes (227,923 control subjects) and 655,250 patients with type 2 diabetes (655,250 control subjects) were followed for a median of 14.1 and 7.9 years, respectively. Of those, 153 and 7,197, respectively, had phenotypic FH. Compared with control subjects, patients with diabetes and phenotypic FH had higher risk of cardiovascular mortality (type 1: hazard ratio 21.3 [95% CI 14.6-31.0]; type 2: 2.40 [2.19-2.63]) and of a cardiovascular event (type 1: 15.1 [11.1-20.5]; type 2: 2.73 [2.58-2.89]). Further, patients with diabetes and phenotypic FH had higher LDL-cholesterol levels during observation (P < 0.05) and increased risk of all major cardiovascular outcomes (P < 0.0001) than patients with diabetes but without FH. The proportion receiving lipid-lowering treatment was higher in patients with phenotypic FH (P < 0.0001). CONCLUSIONS: Patients with both diabetes and phenotypic FH are more at risk for adverse cardiovascular outcomes and have higher LDL-cholesterol levels despite receiving intensified lipid-lowering therapy.
引用
- Brinck J, Hagström E, Nåtman J, et al. Cardiovascular Outcomes in Patients With Both Diabetes and Phenotypic Familial Hypercholesterolemia: A Nationwide Register-Based Cohort Study. Diabetes Care. 2022. PMID: 36326759. doi:10.2337/dc22-1025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。